Global Adult Malignant Glioma Therapeutics Market, By Type (Astrocytomas, Ependymomas, Oligodendrogliomas, Glioblastoma, Others), Therapy (Chemotherapy, Targeted Drug Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Adult Malignant Glioma Therapeutics Market Analysis and Size
The global adult malignant glioma therapeutics market is expected to witness significant growth during the forecast period. Emerging markets and considerable investments in research and development are the factors responsible for the growth of this market. Growing cases of brain tumor drive the adult malignant glioma therapeutics market. Due to the acceptance of an unhealthy lifestyle, genetic modification, increased age, excessive exposure to radiation and family history with brain cancer also boost up the adult malignant glioma therapeutics market growth. Elderly people are more likely to get cancer sooner in life, typically before the age of 50. To a lesser extent, there is also a higher risk of acquiring other types of cancer, such as prostate cancer, melanoma, and pancreatic cancer. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global adult malignant glioma therapeutics market in the forecast period 2022-2029. The expected CAGR of global adult malignant glioma therapeutics market is tend to be around 9.50% in the mentioned forecast period. The market was valued at USD 2 billion in 2021, and it would grow upto USD 4.13 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Malignant glioma is a broad category of brain and spinal cord tumors that comes from the brain glial cells that support the brain's nerve cells. Three types of glial cells (Gliomas) can develop tumor. Gliomas are classified according to the tumor genetic features & glial cell involved in the tumor, which can help to predict how the tumor will behave over time. Gliomas are most common in adults between the ages 45 and 65, and almost 80% of malignant brain tumors are gliomas. Symptoms of glioma include headache, nausea or vomiting, confusion, decreased brain function, memory loss, seizures, vision problems, and others. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Adult Malignant Glioma Therapeutics Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Astrocytomas, Ependymomas, Oligodendrogliomas, Glioblastoma, Others), Therapy (Chemotherapy, Targeted Drug Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Genetech Inc. (U.S.), Emcure (India), STI Pharma (U.S.), Navinta LLC. (U.S.)
Global Adult Malignant Glioma Therapeutics Market Dynamics
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the global hematuria treatment market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015 and the possibility of getting infected with ovarian cancer also rises high. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
- Increased Cases of Glioma
According to the Case Reports in Oncology, 2018, approximately 200 cases were reported worldwide for glioblastoma multiforme. As a result, the market gains more attention and the growth is high due to the higher incidence of this diseased condition.
- Rising Healthcare Awareness
Health awareness amongst the population are rising, resulting in the prediction of drugs to boost market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching drugs that benefit the market.This creates more opportunities in the market.
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the treatment methods for this disease could curb the growth of the global adult malignant glioma therapeutics market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global adult malignant glioma therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global adult malignant glioma therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Adult Malignant Glioma Therapeutics Market Scope
The global adult malignant glioma therapeutics market is segmented on the basis of type, therapy, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Targeted Drug Therapy
Route of Administration
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Adult Malignant Glioma Therapeutics Market Regional Analysis/Insights
The global adult malignant glioma therapeutics market is analysed and market size insights and trends are provided by tumor type, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global adult malignant glioma therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacture of the product, high R&D and healthcare expenditure and skilled professionals.
Asia-Pacific dominates the market due to increased government awareness programs and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Adult Malignant Glioma Therapeutics Market Share Analysis
The global adult malignant glioma therapeutics market overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global adult malignant glioma therapeutics market.
Key players operating in the global adult malignant glioma therapeutics market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Genetech Inc. (U.S.)
- Emcure (India)
- STI Pharma (U.S.)
- Navinta LLC. (U.S.)
Research Methodology: Global Adult Malignant Glioma Therapeutics Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.